Client News

Nyxoah Reports Second Quarter Financial and Operating Results

Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®

Formycon Confirms Full-Year Guidance Following Business Development in line with Plan – Working Capital Raised

Newron Begins Enrollment in Pivotal Phase III ENIGMA-TRS Program with evenamide as Add-on Therapy in Patients with Treatment-Resistant Schizophrenia (TRS)

Nyxoah Announces Preliminary Results for the Second Quarter of 2025

NewronNotes the Publication of New Preclinical Research Suggesting Evenamide Ameliorates Schizophrenia-Related Dysfunction

Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea

InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update

DEBRA Research Collaborates with Queen Mary University of London to Advance Drug Development for Epidermolysis bullosa

InflaRx to Report Second Quarter 2025 Results on August 7, 2025